ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,10192
-0,05%
Bitcoin
66.636,17
-0,45%
Brent Oil
83,76
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Mustang Bio Inc (MBIO)

  7. Mustang Bio Inc (MBIO) Notícias

MBIO

Mustang Bio (MBIO)

Mustang Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MBIO
DataHoraFonteTítuloCódigoCompanhia
13/05/202407:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
02/05/202417:01GlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
29/04/202421:00GlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
28/03/202410:00GlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
11/03/202417:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
11/03/202417:05GlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
11/03/202417:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
07/03/202409:30GlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
11/01/202410:30GlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
19/12/202318:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
11/12/202323:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
11/12/202310:30GlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
14/11/202318:05GlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
03/11/202316:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MBIOMustang Bio Inc
02/11/202310:28GlobeNewswire Inc.Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
30/10/202315:15GlobeNewswire Inc.Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
30/10/202311:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
26/10/202313:30GlobeNewswire Inc.Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
26/10/202310:00GlobeNewswire Inc.Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaNASDAQ:MBIOMustang Bio Inc
14/08/202317:01GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
14/08/202317:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBIOMustang Bio Inc
07/07/202317:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
30/06/202309:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MBIOMustang Bio Inc
15/05/202317:01GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
28/04/202317:19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MBIOMustang Bio Inc
28/04/202317:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MBIOMustang Bio Inc
14/04/202317:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MBIOMustang Bio Inc
06/04/202317:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:MBIOMustang Bio Inc
03/04/202317:50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MBIOMustang Bio Inc
30/03/202317:10GlobeNewswire Inc.Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MBIO

Seu Histórico Recente

LSE
0DYX
Ubs-etf Sbi Foreign Aaa-...
LSE
0MGR
Forvia
NASDAQ
AREC
American Resources
LSE
FSFL
Foresight Solar
LSE
UOG
United Oil & Gas
NYSE
RRMS
LSE
RRR
Red Rock Resources
BOV
CSED3M
Cruzeiro do Sul Educacio... ON
NYSE
QBTS
D Wave Quantum
BOV
USIME820
USIME820 Ex:7,92
LSE
VENN
Venn Life Sciences
LSE
RTOP
Regtech Open Project
LSE
0HDS
Ubs Etf - Msci Emu Soc R...
LSE
0Q7U
Fluxys Belgium
BMF
ISPM24
ISPM24 - Junho 2024
LSE
ENET
Ethernity Networks
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados